Potential of mTOR inhibitors as therapeutic agents in hematological malignancies

Expert Review of Hematology

Volumn 2, Issue 4, 2009, Pages 399-414

  Sankhala, Kamalesh ^a   Giles, Francis J ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

AML; Hematological; Leukemia; Malignancies; MTOR inhibitors; PIM kinase; Targeted therapy

Indexed keywords

AFINITOR; DEFOROLIMUS; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MK 8669; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN DERIVATIVE; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANEMIA; ANOREXIA; APHTHOUS ULCER; ASTHENIA; BIPOLAR DISORDER; BONE MARROW SUPPRESSION; CANCER MORTALITY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CYTOPENIA; DEHYDRATION; DIARRHEA; ELECTROLYTE DISTURBANCE; FATIGUE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; INTERSTITIAL PNEUMONIA; MORBIDITY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RASH; REVIEW; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 77953433400     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.31     Document Type: Review

References (170)

1. Raught B, Gingras AC, Sonenberg N. The target of rapamycin (TOR) proteins. Proc. Natl Acad. Sci. USA 98(13), 7037-7044 (2001).
2. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/ mTOR. Genes Dev. 15(7), 807-826 (2001).
3. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/ eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 24(1), 200-216 (2004).
4. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 103(2), 253-262 (2000).
5. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4(2), 147-158 (2003).
6. Jung CH, Jun CB, Ro S-H et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol. Biol. Cell 20(7), 1992-2003 (2009).
7. Brown EJ, Albers MW, Shin TB et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369(6483), 756-758 (1994).
8. Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc. Natl Acad. Sci. USA 91(26), 12574-12578 (1994).
9. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253(5022), 905-909 (1991).
10. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78(1), 35-43 (1994).
11. Sabers CJ, Martin MM, Brunn GJ et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem. 270(2), 815-822 (1995).
12. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4(12), 988-1004 (2005).
13. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. 12(18), 5268-5272 (2006).
14. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl Cancer Inst. 92(18), 1472-1489 (2000).
15. Yu Y, Sato JD. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J. Cell Physiol. 178(2), 235-246 (1999).
16. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin. Biochem. 31(5), 335-340 (1998).
17. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. 28(10), 727-732 (1975).
18. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. 28(10), 721-726 (1975).
19. Calne RY, Collier DS, Lim S et al. Rapamycin for immunosuppression in organ allografting. Lancet 2(8656), 227 (1989).
20. Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can. J. Physiol. Pharmacol. 55(1), 48-51 (1977).
21. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 356(9225), 194-202 (2000).
22. MacDonald AS. A worldwide, Phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71(2), 271-280 (2001).
23. Douros J, Suffness M. The National Cancer Institute's natural products antineoplastic development program. Recent Results Cancer Res. 70, 21-44 (1980).
24. Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat. Rev. 8(1), 63-87 (1981).
25. Eng CP, Sehgal SN, Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J. Antibiot. 37(10), 1231-1237 (1984).
26. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon ?, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007). (Pubitemid 46849157)
27. Kay A, Motzer R, Figlin R et al. Updated data from a Phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). Presented at: 44th Annual Meeting of American Society of Clinical Oncology, Chicago USA, 30 May-3 June 2008 (Abstract 278).
28. Dancey JE. Clinical development of mammalian target of rapamycin inhibitors. Hematol. Oncol. Clin. North Am. 16(5), 1101-1114 (2002).
29. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr. Opin. Investig. Drugs 3(2), 295-304 (2002).
30. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 58(19), 4375-4382 (1998).
31. Andrade MA, Bork P. HEAT repeats in the Huntington's disease protein. Nat. Genet. 11(2), 115-116 (1995).
32. Groves MR, Barford D. Topological characteristics of helical repeat proteins. Curr. Opin. Struct. Biol. 9(3), 383-389 (1999).
33. Groves MR, Hanlon N, Turowski P, Hemmings BA, Barford D. The structure of the protein phosphatase 2A PR65/A subunit reveals the conformation of its 15 tandemly repeated HEAT motifs. Cell 96(1), 99-110 (1999).
34. Cafferkey R, Young PR, McLaughlin MM et al. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol. Cell. Biol. 13(10), 6012-6023 (1993).
35. Alarcon CM, Heitman J, Cardenas ME. Protein kinase activity and identification of a toxic effector domain of the target of rapamycin TOR proteins in yeast. Mol. Biol. Cell. 10(8), 2531-2546 (1999).
36. Bosotti R, Isacchi A, Sonnhammer EL. FAT: a novel domain in PIK-related kinases. Trends Biochem. Sci. 25(5), 225-227 (2000).
37. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. 3(4), 371-377 (2003). (Pubitemid 36908940)
38. Jacinto E, Hall MN. Tor signalling in bugs, brain and brawn. Nat. Rev. Mol. Cell Biol. 4(2), 117-126 (2003).
39. Loewith R, Jacinto E, Wullschleger S et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10(3), 457-468 (2002).
40. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6(9), 729-734 (2006).
41. Sarbassov DD , Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712), 1098-1101 (2005).
42. Sarbassov DD , Ali SM, Sengupta S et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22(2), 159-168 (2006).
43. Zeng Z, Sarbassov dos D, Samudio IJ et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109(8), 3509-3512 (2007).
44. Kim DH, Sarbassov DD , Ali SM et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110(2), 163-175 (2002).
45. Kim DH, Sarbassov DD , Ali SM et al. G?L, a positive regulator of the rapamycinsensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 11(4), 895-904 (2003).
46. Hara K, Maruki Y, Long X et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110(2), 177-189 (2002).
47. Yonezawa K, Tokunaga C, Oshiro N, Yoshino K. Raptor, a binding partner of target of rapamycin. Biochem. Biophys. Res. Commun. 313(2), 437-441 (2004).
48. Harris TE, Lawrence JC Jr. TOR signaling. Sci. STKE 2003(212), re15 (2003).
49. Nojima H, Tokunaga C, Eguchi S et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem. 278(18), 15461-15464 (2003).
50. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 124(3), 471-484 (2006).
51. Dunlop EA, Tee AR. Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell. Signal. 21(6), 827-835 (2009).
52. Sancak Y, Thoreen CC, Peterson TR et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25(6), 903-915 (2007).
53. Thedieck K, Polak P, Kim ML et al. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS ONE 2(11), e1217 (2007).
54. Bai X, Ma D, Liu A et al. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 318(5852), 977-980 (2007).
55. Uhlenbrock K, Weiwad M, Wetzker R, Fischer G, Wittinghofer A, Rubio I. Reassessment of the role of FKBP38 in the Rheb/mTORC1 pathway. FEBS Lett. 583(6), 965-970 (2009).
56. Sato T, Nakashima A, Guo L, Tamanoi F. Specific activation of mTORC1 by RHEB G-protein in vitro involves enhanced recruitment of its substrate protein. J. Biol. Chem. 284(19), 12783-12791 (2009).
57. Sarbassov DD , Ali SM, Kim DH et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14(14), 1296-1302 (2004).
58. Frias MA, Thoreen CC, Jaffe JD et al. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr. Biol. 16(18), 1865-1870 (2006).
59. Jacinto E, Loewith R, Schmidt A et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6(11), 1122-1128 (2004).
60. Rosner M, Hengstschlager M. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum. Mol. Genet. 17(19), 2934-2948 (2008).
61. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275(5300), 665-668 (1997).
62. Stokoe D, Stephens LR, Copeland T et al. Dual role of phosphatidylinositol-3,4,5- trisphosphate in the activation of protein kinase B. Science 277(5325), 567-570 (1997).
63. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 294(5548), 1942-1945 (2001).
64. Wing LY, Chen HM, Chuang PC, Wu MH, Tsai SJ. The mammalian target of rapamycin-p70 ribosomal S6 kinase but not phosphatidylinositol 3-kinase-Akt signaling is responsible for fibroblast growth factor-9-induced cell proliferation. J. Biol. Chem. 280(20), 19937-19947 (2005).
65. McCubrey JA, Steelman LS, Chappell WH et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 1773(8), 1263-1284 (2007).
66. Steelman LS, Abrams SL, Whelan J et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 22(4), 686-707 (2008).
67. Ricciardi MR, McQueen T, Chism D et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia 19(9), 1543-1549 (2005).
68. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 18(16), 1926-1945 (2004).
69. Gao X, Zhang Y, Arrazola P et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell Biol. 4(9), 699-704 (2002).
70. Long X, Ortiz-Vega S, Lin Y, Avruch J. Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J. Biol. Chem. 280(25), 23433-23436 (2005).
71. Sancak Y, Peterson TR, Shaul YD et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320(5882), 1496-1501 (2008).
72. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115(5), 577-590 (2003).
73. Gwinn DM, Shackelford DB, Egan DF et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30(2), 214-226 (2008).
74. Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J. Biol. Chem. 278(32), 29655-29660 (2003).
75. Brugarolas J, Lei K, Hurley RL et al. Regulation of mTOR function in response to hypoxia by REDD 1 and the TSC1/ TSC2 tumor suppressor complex. Genes Dev. 18(23), 2893-2904 (2004).
76. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1/2- mTOR signaling and tumor suppression through REDD 1-mediated 14-13-3 shuttling. Genes Dev. 22(2), 239-251 (2008).
77. Feng Z, Hu W, de Stanchina E et al. The regulation of AMPK ?1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 67(7), 3043-3053 (2007).
78. Dames SA, Mulet JM, Rathgeb-Szabo K, Hall MN, Grzesiek S. The solution structure of the FATC domain of the protein kinase target of rapamycin suggests a role for redox-dependent structural and cellular stability. J. Biol. Chem. 280(21), 20558-20564 (2005).
79. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 25(6), 511-518 (2002).
80. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl Acad. Sci. USA 101(37), 13489-13494 (2004).
81. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem. 68, 913-963 (1999).
82. Hentze MW. eIF4G: a multipurpose ribosome adapter? Science 275(5299), 500-501 (1997).
83. Lin TA, Kong X, Haystead TA et al. PHAS-I as a link between mitogen-activated protein kinase and translation initiation. Science 266(5185), 653-656 (1994).
84. Pause A, Belsham GJ, Gingras AC et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5́-cap function. Nature 371(6500), 762-767 (1994).
85. Marcotrigiano J, Gingras AC, Sonenberg N, Burley SK. Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G. Mol. Cell 3(6), 707-716 (1999).
86. Mendez R, Myers MG Jr, White MF, Rhoads RE. Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase. Mol. Cell. Biol. 16(6), 2857-2864 (1996).
87. Rosenwald IB, Kaspar R, Rousseau D et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J. Biol. Chem. 270(36), 21176-21180 (1995).
88. Rousseau D, Kaspar R, Rosenwald I, Gehrke L, Sonenberg N. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc. Natl Acad. Sci. USA 93(3), 1065-1070 (1996).
89. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J. Biol. Chem. 273(23), 14424-14429 (1998).
90. Shantz LM, Pegg AE. Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res. 54(9), 2313-2316 (1994).
91. Schalm SS, Blenis J. Identification of a conserved motif required for mTOR signaling. Curr. Biol. 12(8), 632-639 (2002).
92. Volarevic S, Thomas G. Role of S6 phosphorylation and S6 kinase in cell growth. Prog. Nucleic Acid Res. Mol. Biol. 65, 101-127 (2001).
93. Pullen N, Dennis PB, Andjelkovic M et al. Phosphorylation and activation of p70s6k by PDK1. Science 279(5351), 707-710 (1998).
94. Park IH, Bachmann R, Shirazi H, Chen J. Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin. J. Biol. Chem. 277(35), 31423-31429 (2002). (Pubitemid 34968942)
95. Barth-Baus D, Stratton CA, Parrott L et al. S6 phosphorylation- independent pathways regulate translation of 5́-terminal oligopyrimidine tract-containing mRNAs in differentiating hematopoietic cells. Nucleic Acids Res. 30(9), 1919-1928 (2002).
96. Hietakangas V, Cohen S. TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells. BMC Cancer 8(1), 282 (2008).
97. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8(3), 179-183 (2005).
98. Um SH, Frigerio F, Watanabe M et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431(7005), 200-205 (2004).
99. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26(13), 1932-1940 (2007).
100. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J. Clin. Invest. 115(10), 2618-2624 (2005).
101. Bachmann M, Moroy T. The serine/ threonine kinase Pim-1. Int. J. Biochem. Cell Biol. 37(4), 726-730 (2005).
102. Meeker TC, Nagarajan L, ar-Rushdi A, Rovera G, Huebner K, Croce CM. Characterization of the human PIM-1 gene: a putative proto-oncogene coding for a tissue specific member of the protein kinase family. Oncogene Res. 1(1), 87-101 (1987).
103. Lilly M, Sandholm J, Cooper JJ, Koskinen PJ, Kraft A. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2- dependent pathway. Oncogene 18(27), 4022-4031 (1999).
104. Pircher TJ, Zhao S, Geiger JN, Joneja B, Wojchowski DM. Pim-1 kinase protects hematopoietic FDC cells from genotoxininduced death. Oncogene 19(32), 3684-3692 (2000).
105. Lilly MB, Holder S, Zemskova M, Neidigh J. Use of a homology model of the PIM-1 kinase to identify variant flavonoids having selective inhibitory activity against PIM-1. Blood (ASH Annual Meeting Abstracts) 104, (2004) (Abstract 2566).
106. van Lohuizen M, Verbeek S, Krimpenfort P et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 56(4), 673-682 (1989).
107. Akasaka H, Akasaka T, Kurata M et al. Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays. Cancer Res. 60(9), 2335-2341 (2000).
108. Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, Telerman A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc. Natl Acad. Sci. USA 86(22), 8857-8861 (1989).
109. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl Acad. Sci. USA 95(26), 15587-15591 (1998).
110. Mirza AM, Kohn AD, Roth RA, McMahon M. Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/PKB. Cell Growth Differ. 11(6), 279-292 (2000).
111. Ruggero D, Montanaro L, Ma L et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 10(5), 484-486 (2004).
112. Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am. J. Pathol. 169(6), 2171-2180 (2006).
113. Goy A, Feldman T. Expanding therapeutic options in mantle cell lymphoma. Clin. Lymphoma Myeloma 7(Suppl. 5), S184-S191 (2007).
114. Hipp S, Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica 90(10), 1433-1434 (2005).
115. Leseux L, Hamdi SM, Al Saati T et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 108(13), 4156-4162 (2006).
116. Pogue SL, Kurosaki T, Bolen J, Herbst R. B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase. J. Immunol. 165(3), 1300-1306 (2000).
117. Hitomi T, Yanagi S, Inatome R, Ding J, Takano T, Yamamura H. Requirement of Syk-phospholipase C-?2 pathway for phorbol ester-induced phospholipase D activation in DT40 cells. Genes Cells 6(5), 475-485 (2001).
118. Hitomi T, Yanagi S, Inatome R, Yamamura H. Cross-linking of the B cell receptor induces activation of phospholipase D through Syk, Btk and phospholipase C-?2. FEBS Lett. 445(2-3), 371-374 (1999).
119. Vega F, Medeiros LJ, Leventaki V et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinasepositive anaplastic large cell lymphoma. Cancer Res. 66(13), 6589-6597 (2006).
120. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosminanaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/ Akt antiapoptotic signaling pathway. Blood 96(13), 4319-4327 (2000).
121. Slupianek A, Nieborowska-Skorska M, Hoser G et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/ anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 61(5), 2194-2199 (2001).
122. Wanner K, Hipp S, Oelsner M et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br. J. Haematol. 134(5), 475-484 (2006).
123. Zhang J, Choi Y, Mavromatis B, Lichtenstein A, Li W. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway. Oncogene 22(40), 6289-6295 (2003).
124. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20(42), 5991-6000 (2001). (Pubitemid 32955041)
125. Hsu JH, Shi Y, Frost P et al. Interleukin-6 activates phosphoinositol-3́ kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways. Oncogene 23(19), 3368-3375 (2004).
126. Liu P, Leong T, Quam L et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III trial. Blood 88(7), 2699-2706 (1996).
127. Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 101(8), 3126-3135 (2003).
128. Pene F, Claessens YE, Muller O et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 21(43), 6587-6597 (2002).
129. Yan H, Frost P, Shi Y et al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res. 66(4), 2305-2313 (2006).
130. Tai YT, Podar K, Mitsiades N et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-?B signaling. Blood 101(7), 2762-2769 (2003).
131. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106(1), 296-303 (2005).
132. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J. Clin. Oncol. 23(26), 6333-6338 (2005).
133. Mitsiades CS, Mitsiades NS, McMullan CJ et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 107(3), 1092-1100 (2006).
134. Min YH, Eom JI, Cheong JW et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 17(5), 995-997 (2003).
135. Dos Santos C, Recher C, Demur C, Payrastre B. The PI3K/Akt/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia. Bull. Cancer 93(5), 445-447 (2006).
136. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102(3), 972-980 (2003).
137. Zhao S, Konopleva M, Cabreira-Hansen M et al. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 18(2), 267-275 (2004).
138. Tamburini J, Elie C, Bardet V et al. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 110(3), 1025-1028 (2007).
139. Avellino R, Romano S, Parasole R et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 106(4), 1400-1406 (2005).
140. Brown VI, Fang J, Alcorn K et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc. Natl Acad. Sci. USA 100(25), 15113-15118 (2003).
141. Brown VI, Hulitt J, Fish J et al. Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7R signaling. Cancer Res. 67(20), 9963-9970 (2007).
142. Teachey DT, Obzut DA, Cooperman J et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107(3), 1149-1155 (2006).
143. Xu Q, Thompson JE, Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 106(13), 4261-4268 (2005).
144. Tamburini J, Chapuis N, Bardet V et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111(1), 379-382 (2008).
145. Calabro A, Tai J, Allen SL, Budman DR. In vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia. Anticancer Drugs 19(7), 705-712 (2008).
146. Nishioka C, Ikezoe T, Yang J, Koeffler HP, Yokoyama A. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia 22(12), 2159-2168 (2008).
147. Hirase C, Maeda Y, Takai S, Kanamaru A. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: possible clinical application of mTOR inhibitor. Leuk. Res. 33(3), 450-459 (2009).
148. Teachey DT, Sheen C, Hall J et al. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 112(5), 2020-2023 (2008).
149. Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res. 63(18), 5716-5722 (2003).
150. Burchert A, Wang Y, Cai D et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19(10), 1774-1782 (2005).
151. Mayerhofer M, Aichberger KJ, Florian S et al. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J. 19(8), 960-962 (2005).
152. Parmar S, Smith J, Sassano A et al. Differential regulation of the p70 S6 kinase pathway by interferon (IFN?) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood 106(7), 2436-2443 (2005).
153. Yoon P, Giafis N, Smith J et al. Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR- ABL-expressing cells. Mol. Cancer Ther. 5(11), 2815-2823 (2006).
154. Raymond E, Alexandre J, Faivre S et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 22(12), 2336-2347 (2004).
155. Hidalgo M, Buckner JC, Erlichman C et al. A Phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin. Cancer Res. 12(19), 5755-5763 (2006).
156. Ghobrial I, Munshi N, Schlossman R et al. Phase I trial of CCI-779 (temsirolimus) and weekly bortezomib in relapsed and/or refractory multiple myeloma 50th ASH Annual Meeting and Exposition (2008) (Abstract 3696).
157. Witzig TE, Geyer SM, Ghobrial I et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. 23(23), 5347-5356 (2005).
158. Ansell SM, Inwards DJ, Rowland KM Jr. et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a Phase 2 trial in the North Central Cancer Treatment Group. Cancer 113(3), 508-514 (2008).
159. Hess G. Romaguera JE, Verhoef G et al. Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice therapy. J. Clin. Oncol. 26(Suppl. 20), (2008) (Abstract 8513).
160. Smith SM, Pro B, Cisneros A et al. Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes. ASCO Annual Meeting Proceedings 26(15S Suppl. 20), (2008) (Abstract 8514).
161. Farag SS, Zhang S, Miller M et al. Phase II trial of temsirolimus (CCI-779) in patients with relapsed or refractory multiple myeloma (MM): preliminary results. J. Clin. Oncol. 24(18S), 7616 (2006).
162. Yee KW, Garcia-Manero G, Thomas D et al. A Phase II study of temsirolimus (CCI-779) in patients with advanced leukemias. Blood (ASH Annual Meeting Abstracts) 104, (2004) (Abstract 4523).
163. Yee KW, Zeng Z, Konopleva M et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 12(17), 5165-5173 (2006).
164. Johnston PB, Ansell SM, Colgan JP et al. Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma. ASCO Annual Meeting Proceedings Part I. 25(18S), (2007) (Abstract 8055).
165. Reeder CB, Gornet MK, Habermann TM et al. A Phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-Hodgkin lymphoma (NHL). ASH Annual Meeting Abstracts, 110(11), (2007) (Abstract 121).
166. Johnston PB, Ansell SM, Colgan JP et al. mTOR Inhibition for relapsed or refractory Hodgkin lymphoma: promising single agent activity with everolimus (RAD001). ASH Annual Meeting Abstracts, 110(11), (2007) (Abstract 2555).
167. Ghobrial IM, Chuma S, Sam A et al. Phase II Trial of the mTOR inhibitor RAD001 in relapsed and/or refractory Waldenstrom macroglobulinemia: the Dana Farber Cancer Institute experience. ASH Annual Meeting Abstracts 112(11), (2008) (Abstract 1011).
168. Mita MM, Mita AC, Chu QS et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J. Clin. Oncol. 26(3), 361-367 (2008).
169. Mita MM Britten CD, Poplin E, et al. Deforolimus trial 106. A phase I trial evaluating 7 regimens of oral deforolimus (AP23573, MK-8669). J. Clin. Oncol. 20(Suppl. 3509), (2008) (Abstract 3509).
170. Rizzieri DA, Feldman E, Dipersio JF et al. A Phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 14(9), 2756-2762 (2008).